Bayer still faces 8,000 Yaz, Yasmin lawsuitsNov 19, 2012
Despite already spending more than $750 million on settlements related to injuries caused by its contraceptive drugs Yaz and Yasmin, Bayer AG may pay at least that much more to settle the remaining and future lawsuits filed against it.
According to an update on the legal proceedings regarding Yaz and Yasmin injuries, Bayer states that it has paid at least $750 million in settling 3,490 lawsuits filed by or on behalf of women who suffered deep vein thrombosis or pulmonary embolism while taking the relatively new contraceptive drugs. The company still faces another 3,800 lawsuits which also make those injury claims and those closest to the proceedings believe the pharmaceutical giant will likely spend that much or more to settle those claims.
Many of these lawsuits have been consolidated for pre-trial proceedings as part of a federal Multidistrict Litigation. The MDL process expedites and streamlines pre-trial motions and decisions. This process aims to avoid appeals due to inconsistent rulings.
In addition to that, Bayer still faces another 5,000 personal injury lawsuits filed by or on behalf of women who claim Yaz or Yasmin caused them to suffer other serious injuries to their gallbladder or even sudden death. That means Bayer could spend into the billions of dollars settling claims or through jury awards to victims of the dangerous side effects of these oral contraceptives.
Bayer has faced more than 12,000 lawsuits already related to injuries caused or believed to be caused by Yaz or Yasmin. And the estimates on legal costs to date and in the future only account for the lawsuits already filed. More lawsuits filed against Bayer over Yaz and Yasmin injuries are filed daily and despite the now-known risks the drugs pose to women taking them, prescriptions continue to be written.
The drug company has faced more than legal action since it launched Yaz and Yasmin. The company has been subjected to federal fines over its illegal marketing of the contraceptives, including the use of Web ads that completely ignored mentioning the drug's side effects. The company has also faced charges that it hid data showing that women who took Yaz or Yasmin faced a greater risk of deep vein thrombosis or pulmonary embolism than women taking another form of contraceptive.
Bayer launched Yaz and Yasmin in 2006 and since that date, it has been subject to widespread speculation despite heavy marketing campaigns that touted the benefits of the drug, including the ease in taking the drug over traditional contraceptives.